

LETTERS AND
CORRESPONDENCE

Letters and correspondence submitted for possible publication must be identified as such. Text length must not exceed 500 words and five bibliographic references. A single concise figure or table may be included if it is essential to support the communication. Letters not typed double-spaced will not be considered for publication. Letters not meeting these specifications will not be returned to authors. Letters to the Editor are utilized to communicate a single novel observation or finding. Correspondence is to be used to supplement or constructively comment on the contents of a publication in the journal and cannot exceed the restrictions for Letters to the Editor. The Editor reserves the right to shorten text, delete objectional comments, and make other changes to comply with the style of the journal. Permission for publication must be appended as a postscript. Submissions must be sent to Marcel E. Conrad, M.D., Associate Editor, American Journal of Hematology, USA Cancer Center, Mobile, Alabama 36688 to permit rapid consideration for publication.

Married Couple Both With Myeloproliferative Disorder and Chromosome 3 Abnormality

To the Editor: It is known that different genotoxic agents that have an effect on hemopoiesis may induce clonal chromosomal changes. The data obtained from the cytogenetic investigations made predominantly on patients treated with radio- and/or chemotherapy showed that the most common anomalies in the secondary myeloid malignancies are $-7/7q-$, $-5/5q-$, $+8$, $-3/der(3p \text{ or } 3q)$, $der(12p)$, and $t(1;7)(p11;p11)$ [1,2]. Here we describe two cases: a wife and husband both with myeloproliferative disorder (MPD) and chromosome 3 abnormality. In May 1986, the patients had spent some time of intensive agricultural work in the region of Bulgaria most affected by the Chernobyl accident.

The husband, a 67-year-old male (case 1) was hospitalized in December 1989. The blood tests showed: hemoglobin 70 g/l, leukocyte count $12.4 \times 10^9/l$ (1% myeloblasts, 3% myelocytes, 5% metamyelocytes, 11% bands, 56% neutrophils, 1% basophils, 5% monocytes, and 18% lymphocytes), and platelets $216 \times 10^9/l$. The bone marrow was hypercellular with 2% blasts, 27% ring sideroblasts (by iron staining), and trilineage dysplasia. Hypolobulated micromegakaryocytes including mononuclear forms and megakaryocytes with depression anomalies were seen. The cytogenetic analysis of bone marrow established karyotype $46,XY,ins(3;3)(q21.3;q21.3q26.2)$ [50] (Fig. 1A). A diagnosis of refractory anemia with ring sideroblasts was made and the patient was treated only with blood transfusions. During the following 9 months the leukocyte count increased periodically from 7.0 – 9.0 to 11.2 – $15.0 \times 10^9/l$, associated with an increase of the immature granulocytes. In July 1991 the patient developed acute myeloid leukemia (FAB-type M1) and died.

The wife, a 68-year-old female (case 2) was hospitalized in December 1992. The blood test showed hemoglobin 116 g/l, leukocyte count $11.5 \times 10^9/l$ (2% metamyelocytes, 11% bands, 70% segments, 4% monocytes, 13% lymphocytes), and platelets $1,062 \times 10^9/l$. The bone marrow was normocellular with an increased number of megakaryocytic cells (1%). The cytogenetic analysis of bone marrow revealed karyotype $46,XX[24]/$




Fig. 1. Partial G-banding karyotypes of two metaphases from (A) case 1 showing $ins(3;3)(q21.3;q21.3q26.2)$ and (B) case 2 showing $del(3)(p12.2p14.2),del(7)(q21.2q32)$. The breakpoints are indicated with arrows; in case 2 the breakpoints are noted on normal homologues.

$46,XX,del(3)(p12.2p14.2),del(7)(q21.2q32)$ [26] (Fig. 1B). The aggregation induced by collagen, epinephrine, and ADP was increased. The diagnosis of essential thrombocythemia was made and chemotherapy with hydroxyurea and anti-aggregating therapy with indobufen were administered. In January 1995 the patient died because of polyorgan insufficiency as a result of gastric haemorrhage.

The phytohemagglutinin-stimulated peripheral blood of both patients showed normal karyotype patterns. Blood relationship between them as well as data of other etiologic factors that could be acting upon hemopoiesis were not revealed.

The fact that both cases had an MPD with chromosome 3 abnormality could be interpreted as a mere coincidence or as diseases induced by a common noxious agent. In favor of the latter interpretation is the kind of chromosome aberrations found in the patients, since $der(3q)$, $der(3p)$, and $7q-$ are one of the frequent cytogenetic anomalies in secondary myeloid malignancies [1,2]. Moreover, the trilineage bone marrow disorder described in case 1 is a characteristic feature of the secondary myelodysplastic syndrome [3]. To the point, it is also interesting that the breakpoint $3p14.2$ by $3p$ deletion in case 2 concurs with the location of the most sensitive site of normal human chromosomes to aphidicolin-induced breakage [4]. On the other hand, from May 2–6, 1986 the Chernobyl radioactive cloud affected the Balkans, including Bulgaria [5]. The mean daily fallout has been approximately 3,000 times the background value of radioactivity in the region where the patients spent May 1986 engaged in agricultural work. We assume that the ionizing radiation is the etiologic factor that caused the patients' myeloid disorders.

L. MITEV

Department of Cytogenetics, Military Medical Academy, Sofia, Bulgaria

G. GEORGIEV

J. RAYNOV

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

P. NICOLOVA

Department of Disaster Medicine, Military Medical Academy, Sofia, Bulgaria

D. DANCHEV

Central Clinical Laboratory, Military Medical Academy, Sofia, Bulgaria

Y. MANOLOVA

Oncochromosome Laboratory, National Center of Oncology, Sofia, Bulgaria

REFERENCES

1. Heim S: Cytogenetic findings in primary and secondary MDS. *Leuk Res* 16:43–46, 1992.
2. Iurlo A, Mecucci C, Van Orshoven A, Michaux J-L, Boogaerts M, Noens L, Bosly A, Louwagie A, Van Den Berghe H: Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. *Cancer Genet Cytogenet* 43:227–241, 1989.
3. Michels SD, McKeuna RW, Arthur DC, Brunning RD: A clinical and morphological study of 65 cases. *Blood* 65:1364–1372, 1985.
4. Smith DI, Glover TW, Gemmill R, Drabkin H, O'Connell P, Noylor SL: Report of the fifth international workshop on human chromosome 3 mapping 1994. *Cytogenet Cell Genet* 68:26–146, 1995.
5. "Chernobyl: Ten Years On Radiological and Health Impact." Paris: OECD Publications, November 1996, pp 34–36.